Outer Biosciences now feeds live human skin—harvested from discarded surgical tissue and kept viable for more than a month—into machine-learning models. The startup hopes to make drug-discovery and dermatology predictions far more reliable. Its two-year pipeline moves tissue from operating rooms to a lab within hours, a speed the company says preserves the cells’ natural behavior.
Why the old data-sets fall short
For most of biotech’s recent history, researchers have relied on animal models or cultured cell lines to train computational tools. Those systems are cheap and easy to handle, but they rarely capture the full complexity of human skin—a layered organ with immune cells, nerve endings, microbiome interactions and a dynamic response to hormones and stress. The mismatch forces drug developers to run multiple rounds of animal testing and human trials, inflating costs and extending timelines.
Outer Biosciences positions itself as a bridge across that gap. By using tissue that has never been altered in a dish, the company believes its AI can learn patterns invisible to synthetic models. “Living data” is the phrase the team uses to describe the difference between a static snapshot of a cell line and a continuously interacting tissue slice that still communicates with its environment.
From the operating room to the algorithm
The logistical challenge matches the scientific one. Outer Biosciences sources skin that would otherwise be discarded during procedures such as abdominoplasties or mastectomies. Nonprofit and commercial biobanks, operating under Institutional Review Board (IRB) oversight, document donor consent for research use. Once a hospital flags a suitable specimen, the company’s courier network picks it up, transports it in temperature-controlled containers, and delivers it to a processing facility within a few hours.
In the lab, the skin sits in a perfusion system that mimics blood flow, keeping the cells alive for up to 30 days. During that window, the team captures high-resolution imaging, transcriptomics and proteomics data at multiple time points. The multi-modal dataset feeds deep-learning pipelines that predict how the tissue will react to chemical compounds, UV exposure, or inflammatory triggers.
The people pulling the lever
Co-founder and CEO Michael Polansky brings a mathematics background from Harvard and a track record of scaling complex operations, from venture-capital portfolios to global concert tours. Chief Scientist Kyung-Jin Jang, a skin-biology specialist, directs the experimental side, while CTO Chris Hinojosa builds the data-engineering platform that stitches together imaging and molecular streams. The board includes pop-culture icon Lady Gaga, who also chairs the cosmetics brand Haus Labs, a venture that shares research resources with Outer Biosciences.
These cross-industry ties give the startup both the capital to build a niche logistics network and a ready market for early applications. Haus Labs, for example, could test new formulations on the live-tissue platform before moving to human volunteers, potentially shaving weeks off the typical product-development cycle.
What’s at stake
If the approach lives up to its promise, pharmaceutical companies could cut the number of animal studies required for early-stage screening, reducing both cost and ethical concerns. Dermatology clinics might gain AI tools that predict how a patient’s skin will respond to a prescription cream, enabling truly personalized treatment plans. The broader AI community could also benefit from a richer, more realistic training set that pushes the limits of predictive biology.
The model raises questions about scalability and privacy. Collecting tissue from surgery depends on hospitals and donors willing to participate, and the supply chain may bottleneck as demand rises. While biobanks operate under IRB oversight, detailed molecular profiles could, in theory, be linked back to individuals if data-handling practices slip. Critics argue that even with consent, the commercial exploitation of discarded tissue skirts a thin ethical line.
Counter-point: Do organoids still have a role?
Saintis yang membangunkan organoid—kluster sel tiga dimensi yang ditumbuhkan di dalam makmal untuk meniru fungsi organ—menasihatkan agar model-model tersebut tidak dibuang sepenuhnya. Organoid boleh dihasilkan daripada sel stem pluripoten teraruh seorang pesakit, menawarkan platform peribadi tanpa memerlukan tisu pembedahan yang segar. Ia juga membolehkan penyelidik mengkaji proses perkembangan selama berbulan-bulan, sesuatu yang tidak dapat dilakukan oleh hirisan kulit selama 30 hari. Outer Biosciences mengakui bahawa platformnya bukanlah pengganti universal, sebaliknya merupakan sumber data berketepatan tinggi yang melengkapi soalan-soalan khusus di mana seni bina asli kulit adalah paling penting.
Laluan ke hadapan
Outer Biosciences kini sedang menjalankan kajian rintis dengan beberapa rakan kongsi bioteknologi, menguji kuasa ramalan modelnya berbanding hasil ubat yang telah diketahui. Keputusan awal, yang hanya dikongsi dalam taklimat dalaman, menunjukkan korelasi yang lebih tinggi dengan data ujian klinikal berbanding ramalan berasaskan organoid yang setara. Syarikat tersebut merancang untuk memperluas pengumpulan tisunya bagi merangkumi jenis organ lain, walaupun setiap satunya akan membawa cabaran logistik tersendiri.
Pihak pengawal selia masih belum mengeluarkan panduan khusus mengenai model AI yang dilatih menggunakan tisu manusia hidup, namun rangka kerja FDA yang sedang berkembang untuk peranti perubatan dipacu AI berkemungkinan akan bersilang dengan kerja Outer. Syarikat pemula itu menyatakan bahawa ia sedang menyediakan dokumentasi yang memenuhi kedua-dua piawaian privasi data dan jangkaan agensi tersebut untuk ketelusan algoritma.
Kesimpulan
Outer Biosciences telah mengubah satu pencapaian logistik—memindahkan kulit manusia yang segar dari bilik pembedahan ke makmal dalam masa beberapa jam sahaja—menjadi enjin data yang boleh menjadikan ramalan AI tentang ubat-ubatan dan kesihatan kulit lebih dipercayai. Kejayaan usaha ini akan bergantung pada keupayaannya untuk memastikan aliran bekalan tisu berterusan, melindungi privasi penderma, dan membuktikan bahawa "data hidup" sebenarnya mengatasi model sintetik sedia ada. Jika berjaya, kesan riak tersebut boleh dirasai merentasi bidang farmaseutikal, kosmetik dan dermatologi klinikal, sekali gus membentuk semula cara kita melatih mesin untuk memahami tubuh manusia.